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Abstract
Background: Oral delivery is a highly desirable property for candidate drugs under development.
Computational modeling could provide a quick and inexpensive way to assess the intestinal
permeability of a molecule. Although there have been several studies aimed at predicting the
intestinal absorption of chemical compounds, there have been no attempts to predict intestinal
permeability on the basis of peptide sequence information. To develop models for predicting the
intestinal permeability of peptides, we adopted an artificial neural network as a machine-learning
algorithm. The positive control data consisted of intestinal barrier-permeable peptides obtained by
the peroral phage display technique, and the negative control data were prepared from random
sequences.
Results: The capacity of our models to make appropriate predictions was validated by statistical
indicators including sensitivity, specificity, enrichment curve, and the area under the receiver
operating characteristic (ROC) curve (the ROC score). The training and test set statistics indicated
that our models were of strikingly good quality and could discriminate between permeable and
random sequences with a high level of confidence.
Conclusion:  We developed artificial neural network models to predict the intestinal
permeabilities of oligopeptides on the basis of peptide sequence information. Both binary and VHSE
(principal components score Vectors of Hydrophobic, Steric and Electronic properties)
descriptors produced statistically significant training models; the models with simple neural
network architectures showed slightly greater predictive power than those with complex ones.
We anticipate that our models will be applicable to the selection of intestinal barrier-permeable
peptides for generating peptide drugs or peptidomimetics.
Published: 11 July 2007
BMC Bioinformatics 2007, 8:245 doi:10.1186/1471-2105-8-245
Received: 30 March 2007
Accepted: 11 July 2007
This article is available from: http://www.biomedcentral.com/1471-2105/8/245
© 2007 Jung et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Bioinformatics 2007, 8:245 http://www.biomedcentral.com/1471-2105/8/245
Page 2 of 9
(page number not for citation purposes)
Background
Successful drug development requires not only the opti-
mization of pharmacological specificity and potency, but
also a method for efficient drug delivery to the target site.
Many drug candidates fail to achieve their therapeutic
potentials because of poor bioavailability [1]. Oral drug
delivery avoids the pain and discomfort associated with
injections and also the risk of accidents and infections
caused by misuse of needles. For these reasons, the oral
route is by far the easiest and most convenient mode of
drug administration, and oral availability is a highly desir-
able property for candidate drugs under development.
However, before an orally administered drug can reach its
site of action, it must first cross the intestinal epithelial
barrier by passive diffusion, carrier- or receptor-mediated
uptake or active transport and enter the systemic circula-
tion [2]. Molecules with low permeability and/or absorp-
tion rates are not suitable for oral administration, and
there has been great interest in finding ways to avoid pro-
ducing potent but non-permeating molecules [3]. Several
screening paradigms for evaluating drug absorption have
been employed to enhance the probability of success
through the stages of drug development and a number of
methods have been developed to assess oral availability
using in vivo, in vitro, in situ or in silico models [4].
The most widely-accepted in vitro absorption model uses
Caco-2 cell monolayers. Because Caco-2 cells express sev-
eral types of transporter proteins, both the passive and
active transport potentials of a compound can be investi-
gated [5-7] and several experimental methods have been
developed using this model to test the absorption of drugs
by the human intestine [8-10]. However, these experi-
mental cell-system methods are rather labor-intensive and
not easily applicable to high-throughput screening. As an
alternative approach, computational modeling can pro-
vide a quick and inexpensive way of evaluating the intes-
tinal permeability of a compound before synthesis. This
enables us to prioritize molecules for in vitro and in vivo
studies and improve the overall properties of the com-
pounds that proceed along the drug discovery pathway. A
number of models for Caco-2 cell permeability or human
intestinal absorption have been reported that predict the
oral absorption properties of drugs, mostly limited to
small organic molecules [11-14].
Rapid developments in biotechnology and peptide syn-
thesis have made it possible to exploit the unique phar-
macological activities of peptides; thousands of different
peptides have been designed, synthesized and subjected
to a range of screening procedures and biological assays.
To analyze the vast amounts of biological data on pep-
tides, quantitative structure-activity relationship (QSAR)
models have been successfully employed. For example,
several QSAR models have been developed to predict the
peptide binding activities of target proteins, resulting in
good correlations with in vitro data [15-19], and these
have proved useful in generating leads through the screen-
ing of large peptide libraries. It is surprising that QSAR
models have seldom been applied to other pharmacolog-
ical properties of peptides, especially since failure to com-
ply with pharmacological demands is likely to terminate
the development of a candidate peptide drug [20,21].
Although a few previous QSAR studies have investigated
the affinities of peptides to intestinal transport proteins,
the machine-learning processes were performed not on
the basis of sequence information but of chemical struc-
ture [22-24]. There have been a few reports on the predic-
tion of intestinal absorption of non-peptide compounds
from molecular structure. Wessel et al. reported a QSAR
study on a set of 86 compounds with known percentage
human intestinal absorption (%HIA) values [25]. To
obtain a predictive model, they used a neural network to
map molecular structure descriptors to %HIA. Polley et al.
applied Bayesian regularized neural networks to develop
a statistically significant QSAR model for human intesti-
nal absorption [26].
In this work, we report the first QSAR models to predict
the intestinal permeabilities of peptides on the basis of
their sequences. A group of peptides crossing the intesti-
nal barrier were selected from a random phage-peptide
library using the 'peroral phage display technique', a
newly developed in vivo technique in which a phage-pep-
tide library is administered orally to rats and the intestinal
barrier-permeable phages are collected from the internal
organs. Using the sequence set of the selected phage-dis-
played peptides, we constructed an artificial neural net-
work model to evaluate the intestinal permeabilities of
peptides using various descriptors of the physicochemical
properties and occurrence of the amino acid residues.
Results
Using the peroral phage display technique, we identified
852 heptapeptide sequences from phages randomly
selected from 105 ~107 clones translocated from the intes-
tinal lumen to the inner organs such as liver, lung, spleen
and kidney (see the Methods section for details). These
intestinal barrier-permeable peptides were used as the
positive control set for further analysis. Because the phos-
pholipid bilayer is the structural basis of cellular mem-
branes, both hydrophilic and hydrophobic interactions
might affect the intestinal permeability of a molecule. To
evaluate the effects of individual amino acid residues on
the intestinal permeability of a peptide, we compared the
frequencies of occurrence of each residue in the intestinal
barrier-permeable peptides and in the random phage
library (Table 1), then investigated the correlation
between the relative residue frequencies and their hydro-
phobic and hydrophilic properties [27]. We found noBMC Bioinformatics 2007, 8:245 http://www.biomedcentral.com/1471-2105/8/245
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direct relationship between the relative frequency and any
of the hydrophobicity or hydrophilicity indices investi-
gated (Table 1). Obviously, the intestinal permeability of
a peptide is not predictable simply from its hydrophobic-
ity/hydrophilicity, so we proceeded to develop an artifi-
cial neural network model that also takes account of the
peptide sequence in predicting permeability.
First, 852 random heptapeptide sequences were generated
as negative control data, keeping the frequency of each
amino acid residue the same as in the random phage
library. We utilized a feed-forward neural network for our
sequence-based permeability prediction. Eight models
were derived for training data set by varying the type of
peptide descriptor and/or the number of neurons in the
(single) hidden layer. The predictive features of the result-
ing model are illustrated in Figure 1, which clearly shows
that our model can distinguish effectively between intesti-
nal barrier-permeable and impermeable peptides.
Tables 2 shows the accuracy of prediction by our models
for 1:1 data set using binary and VHSE (principal compo-
nents score Vectors of Hydrophobic, Steric and Electronic
properties) descriptors, respectively (see the Methods sec-
tion for details). The receiver operating characteristics
(ROC) score, which is the area under the ROC curve, was
used as the primary yardstick of performance since it pro-
vides an overview of the possible cut-off levels in the test
performance. The table shows that all the models are of
high quality, as assessed by the training and test set statis-
tics; binary descriptors tend to produce slightly better
training models than VHSE descriptors. An increased
number of neurons in the hidden layer improved the abil-
ity of our models to predict the intestinal permeability of
peptide in the training set, however no such tendency was
apparent in the statistics for the test set. This is presumably
due to overtraining of the networks; as the network archi-
tecture becomes more complex, the number of parameters
increases, entailing the risk of overtraining. The effect of
Table 1: Comparison for relative hydrophilicity and hydrophobicity of amino acids for the real data sets.
Hydrophobicity*
Amino acid Hominga Randomb Ratioc Calculatedd Side-chain 
analoguese
Amino acidsf N-acetyl 
amidesg
Hydrophilicity*
Alanine 6.85 6.50 1.05 -0.39 -0.87 -0.50 -0.31 -0.45
Glycine 4.02 2.20 1.83 0.00 0.00 0.00 0.00 0.00
Isoleucine 1.56 2.10 0.74 -1.82 -3.98 -1.80 -1.80 -0.24
Leucine 7.19 9.60 0.75 -1.82 -3.98 -1.80 -1.70 -0.11
Valine 1.98 1.90 1.04 -1.30 -3.10 -1.50 -1.22 -0.40
Methionine 2.69 3.30 0.82 -0.96 -1.41 -1.30 -1.23 -3.87
Phenylalanine 1.56 2.10 0.74 -2.27 -2.04 -2.50 -1.79 -3.15
Tryptophan 0.66 1.90 0.35 -2.13 -1.39 -3.40 -2.25 -8.27
Proline 11.41 10.70 1.07 -0.99 - -1.40 -0.72 -
Cysteine 0.02 0.00 - -0.99 -0.34 -1.00 -1.54 -3.63
Serine 13.42 8.60 1.56 1.24 4.34 0.30 0.04 -7.45
Threonine 10.72 13.10 0.82 1.00 3.51 -0.40 -0.26 -7.27
Tyrosine 1.95 2.40 0.81 -1.47 1.08 -2.30 -0.96 -8.50
Asparagine 6.22 6.40 0.97 1.91 7.58 0.20 0.60 -12.07
Glutamine 7.56 7.10 1.06 1.30 6.48 0.20 0.22 -11.77
Histidine 6.74 6.90 0.98 0.64 5.60 -0.50 -0.13 -12.66
Lysine 5.33 3.80 1.40 2.77 6.49 3.00 0.99 -11.91
Arginine 4.89 4.30 1.14 3.95 15.86 3.00 1.01 -22.31
Aspartic acid 3.06 4.10 0.75 3.81 9.66 2.50 0.77 -13.34
Glutamic acid 2.18 3.10 0.70 2.91 7.75 2.50 0.64 -12.63
Correlation Coefficienth 0.17 0.21 0.40 0.50 0.03
a Observed frequency of each amino acid in the tissue-homing heptapeptide set obtained from peroral phage display
b Observed frequency of each amino acid in the phage library (Ph. D-C7C™ library)
c Relative ratio of amino acid frequency in homing peptidea to amino acid frequency in phage libraryb
d Calculated from hydrophobicities of the individual groups that make up each side chain, using data for the partition coefficient between water and 
octanol of many model compounds.
e Hydrophilicity was measured by the partition coefficient KD of the model for each side chain from vapor → water; hydrophobicity for water → 
cyclohexane. For ionizing side chains, the values were corrected for the fraction of each side chain that is ionized at pH 7. Both scales were 
normalized to zero for the value of Gly.
f Some values were measured from the relative solubilities of the amino acid in water and ethanol or dioxane.
g Measured from the partition coefficient between water and octanol of the N-acetyl amino acid amides.
h Correlation coefficients between relative ratioc and each hydrophobicity/hydrophilicity.
*Reference [26].BMC Bioinformatics 2007, 8:245 http://www.biomedcentral.com/1471-2105/8/245
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overtraining was relatively small for the models based on
VHSE descriptors, which use fewer variables than binary
descriptors.
To test the effect of the number of objects on overtraining,
we also constructed neural network models for 1:3 data
set in which the negative control data set was three times
larger than the positive; Table 2 summarizes the capacity
of these models for prediction. Considering models with
the same network architectures, the differences in ROC
scores between the training and test set were generally
smaller in the 1:3 than the 1:1 data set. This result shows
that the performance of the model is less affected by over-
training if the size of the data set is increased.
Predictive features of the model Figure 1
Predictive features of the model. The model was constructed with zero neuron in a hidden layer and one in an output 
layer using binary descriptors. (A) Enrichment curve, (B) Histogram Actives vs. Model values, and (C) Receiver Operating 
Characteristic (ROC) curve. The features for the training and test set were plotted in the left and right panels, respectively.
Table 2: Prediction accuracy for models with various network architecturesa.
Binary Descriptor VHSE Descriptor
Nhidden
b 1 : 1 Data set 1 : 3 Data set Nhidden
b 1 : 1 Data set 1 : 3 Data set
Training Test Training Test Training Test Training Test
0 0.84 0.77 0.83 0.79 0 0.80 0.76 0.79 0.77
1 0.92 0.73 0.90 0.76 1 0.87 0.70 0.84 0.75
2 0.97 0.71 0.94 0.77 2 0.89 0.71 0.86 0.75
3 0.98 0.71 0.97 0.74 3 0.92 0.70 0.90 0.72
a The network architecture A-B-C indicates the total number of descriptors in an input layer, where A is (7, the sequence length of a peptide) × 
(the number of descriptors for each amino acid), B and C are the numbers of neurons in hidden and output layers, respectively. For instance, the 
network architecture (7 × 20)-0-1 specifies a model constructed with zero neuron in hidden layer and one in output layer using the binary 
descriptor. All the models have one neuron in output layer.
b The number(B) of neurons in a hidden layer.BMC Bioinformatics 2007, 8:245 http://www.biomedcentral.com/1471-2105/8/245
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To validate the sequence dependency, we compared the
intestinal permeabilities of peptides with identical amino
acid compositions but different sequences. We selected
three peptides with different prediction scores from
among the 852 intestinal barrier-permeable heptapep-
tides: TQKSGPV, with a high score (1.03), HKGPFQS,
with a medium score (0.78), and QPMNSLT, with a low
score (0.52). For each of these peptides, we generated a set
of peptides with all the possible sequence permutations of
the seven amino acids (7! = 5040) and intestinal permea-
bilities were predicted using the model with network
architecture (7 × 20)-0-1. The wide distribution of the pre-
diction scores for the peptide sets (Figure 2) clearly indi-
cates that the intestinal permeability of a peptide depends
on its sequence.
To evaluate the robustness of our models, we performed
leave-5%-out cross-validation, which is analogous to
leave-one-out cross-validation [28]: 5% of the sequences
are omitted as validation data. The result of twenty rigor-
ous tests (Table 3) shows only small differences between
the different training runs, indicating that all the models
are quite robust.
To test the reliability of the peptide sequences from the
phage-display experiment as the positive control set and
to validate the strength of our model in predicting the
intestinal permeabilities of peptides, a separate decoy set
was generated as positive control in the training and test
set. We constructed supplementary model trained with
the decoy set and compared that model with the model
trained with the real data set for ability to discriminate
between intestinal barrier-permeable and impermeable
peptides. The predictive features presented in Figure 3
indicate that model constructed with the decoy set do not
discriminate between these two permeability classes of
peptides. Also, the validation result for model with net-
work architecture (7 × 20)-0-1 (Table 3) suggest that the
predictive power for the test set is considerably greater
when the model is constructed with the real set than with
the decoy. This result confirms that model trained with
the real set is robust discriminator between intestinal bar-
rier-permeable and impermeable peptides, and that the
positive real data sequences were collected sufficiently
well to allow efficient model construction.
More detailed statistics about the predictive capacities of
our models are listed in Table 4, which shows a truth table
analysis of the binary outcome based on intestinal perme-
ability. The results show that our models are more sensi-
tive in predicting the intestinal permeabilities of peptides
for 1:1 than for 1:3 data set, while the specificity in screen-
ing out intestinal barrier-impermeable peptides is greater
for 1:3 than for 1:1 data set. Thus, a neural network model
based on 1:1 data set is preferred for selecting intestinal
barrier-permeable peptides, while a model based on 1:3
data set is preferred for eliminating intestinal barrier-
impermeable peptides. The accuracies of prediction by the
models were strikingly high for both 1:1 and 1:3 data set.
Discussion
We have developed models for predicting the intestinal
permeabilities of peptides. Our models produced nearly
Table 3: The results of validation for models with network architecture (7 × 20)-0-1a.
Leave-5%-out cross-validationb Decoy analysisc
1 : 1 Data set Real set Decoy set
Trainingd Testd Training Test Training Test
0.841 ± 0.002 0.760 ± 0.005 0.82 0.74 0.70 0.47
a The network architecture (7 × 20)-0-1 specifies a model constructed with zero neuron in hidden layer and one in output layer using the binary 
descriptor.
b The results of rigorous test using leave-5%-out method in 1:1 data sets.
c Comparison of ROC scores between real and decoy set using non-redundant data.
d The results of 20 rigorous tests are averaged and expressed as mean ± standard deviation.
Distribution of prediction scores for all permutations of  three peptide sequences Figure 2
Distribution of prediction scores for all permutations of 
three peptide sequences.BMC Bioinformatics 2007, 8:245 http://www.biomedcentral.com/1471-2105/8/245
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identical statistics for multiple training runs and effi-
ciently discriminated among peptides on the basis of
intestinal permeability. As shown in the decoy set analy-
sis, models trained with random sequences had no predic-
tion capacity, but the peptide sequences collected from
the in vivo experiment served well as positive control sets
for the QSAR models.
Although we tried to optimize the network architecture
and to minimize overtraining and other related problems
during the course of development, some factors in our
model might cause prediction errors. We assumed that
randomly-selected heptapeptide sequences can be used as
negative controls. This assumption can be rationalized on
the grounds that heptapeptides with random sequences
are very likely to be intestinal barrier-impermeable
because the sequences obtained from the in vivo experi-
ment only covered a very small portion of the entire 'hep-
tapeptide space'. Thus, our model correctly predicts
permeable rather than impermeable peptides. This indi-
cates that a model based on 1:3 data set is preferable for
eliminating intestinal barrier-impermeable peptides if the
random sequences chosen as negative controls do indeed
show negligible intestinal absorption; as shown in Table
4, the specificity of 1:3 data set models is superior to that
of 1:1 data set models. Consequently, our model has the
best predictive power for the selection of the permeable
peptide in relation to the reliability of the data set.
In this work, we developed models for prediction of intes-
tinal permeabilities of peptides using the feed-forward
neural network as an algorithm for training. As shown in
Table 2, some problems could be detected in the feed-for-
ward neural network, which are including overfitting, net-
work architecture optimization, and selection of the best
QSAR model. To avoid shortcomings such as overtraining
which appears to have happened in our models with
larger network complexity, robust QSAR models using the
Bayesian regularized neural network would be more desir-
able [26,29]. The development of QSAR models using the
more robust methods like the Bayesian neural network
would be a fruitful approach of future work in terms of
Table 4: Comparison of truth table statistics for the test sets for two models
Network  1 : 1 Data set 1 : 3 Data set
architecture SEa SPb PPVc NPVd Acce SEa SPb PPVc NPVd Acce
(7 × 20)-0-1 74 67 69 72 70 32 94 65 81 79
(7 × 8)-0-1 70 72 71 70 71 19 96 59 78 76
a SE = Sensitivity : the proportion of all intestinal barrier-permeable peptides correctly predicted, SE = TP/(TP + FN) where TP is the number of 
intestinal barrier-permeable peptides correctly predicted and FN is the number of intestinal barrier-permeable peptides incorrectly predicted as 
impermeable peptides.
b SP = Specificity : the proportion of intestinal barrier-impermeable peptides correctly predicted, SP = TN/(TN + FP) where TN is the number of 
intestinal barrier-impermeable peptides correctly predicted and FP is the number of intestinal barrier-impermeable peptides incorrectly predicted as 
permeable peptides.
c PPV = Positive Predictive Value : the probability that a predicted permeable peptide is in fact a barrier- permeable peptide, PPV = TP/(TP + FP).
d NPV = Negative Predictive Value : the probability that a predicted intestinal barrier-impermeable peptide is in fact impermeable peptide, NPV = 
TN/(TN + FN).
e Acc = Accuracy : the percentage of all predictions that are correct, Acc = (TP + TN)/Total.
The features of the model constructed with the decoy set Figure 3
The features of the model constructed with the 
decoy set. The models were constructed with zero neuron 
in a hidden layer and one in an output layer using binary 
descriptor. (A) Training set and (B) Test set.BMC Bioinformatics 2007, 8:245 http://www.biomedcentral.com/1471-2105/8/245
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predictive ability and robustness of model for intestinal
permeability of peptide.
Burden et al. [17] noted that property-based descriptors
require a more flexible modeling method than binary
descriptors to take account of larger contributions from
cross terms or nonlinearity. However, our models pro-
duced very similar results on the discrimination of intesti-
nal permeability using binary and VHSE descriptors; no
statistically significant difference was observed in their
ROC scores for the test sets.
The models most widely used for predicting passive intes-
tinal absorption are drug-likeness prediction models such
as the Rule of 5 model introduced by Lipinski et al. [30];
they have the advantages of being simple, easy to interpret
and quick to compute. In general, such approaches are
formulated on the basis of group additive methods, so the
predicted intestinal permeability is similar for peptides
consisting of the same numbers and types of amino acids,
even though they may have different sequences. However,
our analysis showed that the intestinal permeability of a
peptide depends on its sequence (Figure 2) and cannot be
explained simply by using the drug-likeness prediction
models of passive transport. Because of its large size, the
peptide-phage complex is expected to be transported
across the intestinal barrier by other mechanisms such as
transcytosis.
Systemic delivery of macromolecules via the oral pathway
remains one of the most challenging problems in the drug
delivery field, and transcytosis may be a mechanism for
transporting therapeutic agents across the intestinal bar-
rier. If a carrier molecule, either a natural ligand or an anti-
body binding to a transcytotic receptor on the intestinal
epithelium, is covalently bound to a therapeutic agent by
a short linker, the conjugate can bind to the cognate recep-
tor and undergo vesicular trafficking across the intestinal
barrier [31]. This 'carrier-drug conjugate' approach has
been tried using drugs conjugated to immunoglobulin G
(IgG), lactoferrin, transferrin or folic acid, all of which
have cognate transcytosis receptors in enterocytes [32]. To
utilize the transcytosis mechanism for an oral drug deliv-
ery system, it is essential to identify ligands that can bind
to the receptors and facilitate efficient transcytosis across
the intestinal barrier. Our QSAR study on the selection of
intestinal barrier-permeable peptides should be applica-
ble to the development of peptide 'carriers' for delivering
large molecules such as proteins and drugs.
Conclusion
We used artificial neural networks to develop the first
models for predicting the intestinal permeabilities of pep-
tides on the basis of sequence information. The high qual-
ity models obtained were capable of making reliable
predictions. These models are expected to find applica-
tions in the selection of intestinal barrier-permeable pep-
tides from large peptide libraries, and the selected
peptides might be used to facilitate the transport of large
molecules across the intestinal barrier.
Methods
Preparation of intestinal barrier-permeable peptides
To identify peptides transported across the intestinal bar-
rier, an in vivo phage display technique was developed
using the disulfide-constrained cyclic M13 phage display
library. This displays random 7 amino acids with 2 flank-
ing cysteines at both ends of the peptide at the N-terminus
of the M13 phage pIII protein (Ph.D.-C7C system: com-
plexity = 1.2 × 109, New England BioLabs, Beverly, Mary-
land). For the first round of biopanning (in vivo selection),
1.2 × 1012 pfu (approximately 1,000 copies for each pep-
tide-coding phage recombinant) of the Ph.D.-C7C library
in 500 μl phosphate-buffered saline (PBS) was adminis-
tered orally to four overnight-starved adult Sprague-Daw-
ley rats (12 weeks old, male; Samtako, Osan, Korea). One
hour after oral administration of the phage library, the
rats were sacrificed by an abdominal incision under deep
anesthesia (ketamine hydrochloride, 80 mg/kg bw; xyla-
zine, 10 mg/kg bw) and perfused via the left ventricle with
120 ml heparin-supplemented DMEM (Dulbecco's Modi-
fied Eagle's Media, GIBCO, USA) to ensure phage clear-
ance from the blood pool. Representative inner organs
(liver, lung, heart, spleen and kidney) were extracted,
roughly chopped separately on a Petri dish and washed
three times with 30 ml ice-cooled PBS. Each drained organ
sample was resuspended in 2 ml TSS [Tissue Suspension
A schematic view of peroral phage display procedure Figure 4
A schematic view of peroral phage display procedure. 
After the third round of biopanning, individual recombinant 
phage was randomly selected from each organ tissue elute 
for analysis of peptide sequences from their genomes.BMC Bioinformatics 2007, 8:245 http://www.biomedcentral.com/1471-2105/8/245
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Solution: DMEM, 1% (w/v) BSA (bovine serum albumin),
10% (v/v) protease inhibitor cocktail (Sigma, USA)] in a
separate 50 ml polycarbonate tube, then homogenized.
The phage transported into each organ across the intesti-
nal barrier were eluted from each homogenized organ tis-
sue sample by vigorous vortexing with 2 ml 0.1 M glycine,
pH 2.0, and centrifugation at 14,000 g for 8 min. Each
supernatant was neutralized with 55–60 μl 2 M Tris base.
The phage eluted from each organ sample were quantified
by titration, suspended in the same volume (100 μl) and
then amplified by infection of an Escherichia coli host ER
2738 (New England BioLabs) for the next round of bio-
panning. The amplified phage samples were concentrated
using 3.3% polyethylene glycol 8,000/0.4 M NaCl
(Sigma, USA) and quantified again by titration. The sec-
ond round of biopanning was initiated by oral adminis-
tration of the newly amplified phage (1.2 × 1012 pfu) to
rats (n = 4). The sequential procedure described above was
named the 'peroral phage display' (Figure 4). After a third
round of biopanning, individual recombinant phage was
randomly selected from each organ eluate for the analysis
of peptide sequences.
Data sets
The positive control data set of peptides that can cross the
intestinal barrier was obtained from the 852 heptapeptide
sequences identified by the peroral phage display experi-
ments. The negative control data set was generated from
random sequences that had the same frequencies of
occurrence of each amino acid residue as in the Ph.D.-
C7C phage library. The random sequences were then com-
pared with the positive control data and any common
sequences were removed from the negative control data.
For 1:1 data sets, the positive and negative control data
comprised the same number of peptides. To evaluate the
effect of data size, we also generated second data set in
which there was three times more negative control than
positive control data. The 2556 random heptapeptide
sequences were used as the negative control in 1:3 data
set. About 80% of each data set was used for network
training and the remaining data were used for the test set
to validate the trained network.
Descriptors
Two types of amino acid descriptors, binary and VHSE,
were used to encode important features of individual pep-
tide sequences. The binary descriptor used a set of 20
binary digits to encode each amino acid (all zeros except
for the one characterizing the given amino acid) [17]. For
example, 7 × 20 = 140 variables were used to encode a
heptapeptide. The VHSE descriptor is a property descrip-
tor composed of 8 variables for each amino acid and char-
acterizes the hydrophobic, steric and electronic properties
of the 20 coded amino acids [33]. For a heptapeptide, 7 ×
8 = 56 variables were used to build models based on this
descriptor.
Neural network model
We used the machine-learning method to drive structure-
activity relationships. The calculations were carried out on
a Pentium 2.2 GHz machine using the nnet of the VR 7.2
package [34] for feed-forward neural networks with a sin-
gle hidden layer and for multinomial log-linear models.
We used a three-layer neural network architecture con-
taining a single hidden layer in which the number of neu-
rons was increased from 0 to 3. This network consisted of
a multilayer system of neurons, with each neuron in a
given layer fully connected to all the neurons in the two
adjacent levels. A neural network was trained to map a set
of input data to a corresponding set of output data by iter-
ative adjustment of the weights. The activation function of
the hidden layer units is the logistic function and the out-
put units are linear. The Broyden-Fletcher-Goldfarb-
Shanno (BFGS) method was used as the optimization
function. To help the optimization process and to avoid
over-fitting, the weight decay was set at 0.001. The maxi-
mum number of iterations for network training was
50,000 and the other parameters were given the default
values set by the nnet of the VR 7.2 package. Before the
learning network was applied, the input value of the pos-
itive control was 0.9 and that of the negative control was
0.1.
Evaluation
To score the models, the ROC score, which is the area
under the ROC curve [35], was used for each training and
test set. The score is 1 for a perfect classification and 0.5 for
a random classification. All the ROC scores reported were
generated from a leave-group-out cross-validation of real
and decoy set.
Validation using decoy set
We prepared supplementary model trained with decoy set
[36] and compared that model with the model trained
with real data set for the ability to discriminate between
intestinal barrier-permeable and impermeable peptides.
The positive as well as the negative control data of the
decoy set was generated from random peptides. The decoy
set was prepared carefully to ensure that there was no
redundant peptide in the positive control data and no
overlap between the positive and the negative control
data. To ensure the consistency of data, non-redundant
peptide subset of the real set was also prepared; the posi-
tive control data set prepared comprised 677 peptides.
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